Drugs / Angiocal®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01141257 | May 2010 → Sep 2011 | cancer | Pieris Pharmaceuticals GmbH | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Angiocal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01141257 ↗ |
| Known as | PRS-050 | “First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.” PMID 24349470 ↗ Dec 2013 |
| Known as | PRS-050-PEG40 | “Angiocal® (PRS-050-PEG40)” NCT01141257 ↗ |
| Action | Inhibit | “targets and antagonizes vascular endothelial growth factor A (VEGF-A)” PMID 24349470 ↗ Dec 2013 |
| Modality | Protein / enzyme biologic | “a novel, rationally engineered Anticalin based on human tear lipocalin” PMID 24349470 ↗ Dec 2013 |
| Route | Intravenous | “administered intravenously to patients with solid tumors” NCT01141257 ↗ |
| Target | VEGFA | “targets and antagonizes vascular endothelial growth factor A (VEGF-A)” PMID 24349470 ↗ Dec 2013 |